146 related articles for article (PubMed ID: 35358302)
1. Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts.
Li R; Zhu J; Zhong WD; Jia Z
Cancer Res; 2022 May; 82(9):1832-1843. PubMed ID: 35358302
[TBL] [Abstract][Full Text] [Related]
2. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
3. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
[TBL] [Abstract][Full Text] [Related]
4. Extended application of genomic selection to screen multiomics data for prognostic signatures of prostate cancer.
Li R; Wang S; Cui Y; Qu H; Chater JM; Zhang L; Wei J; Wang M; Xu Y; Yu L; Lu J; Feng Y; Zhou R; Huang Y; Ma R; Zhu J; Zhong W; Jia Z
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32898860
[TBL] [Abstract][Full Text] [Related]
5. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
6. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.
Tang H; Wang S; Xiao G; Schiller J; Papadimitrakopoulou V; Minna J; Wistuba II; Xie Y
Ann Oncol; 2017 Apr; 28(4):733-740. PubMed ID: 28200038
[TBL] [Abstract][Full Text] [Related]
8. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
9. Reference-free transcriptome signatures for prostate cancer prognosis.
Nguyen HTN; Xue H; Firlej V; Ponty Y; Gallopin M; Gautheret D
BMC Cancer; 2021 Apr; 21(1):394. PubMed ID: 33845808
[TBL] [Abstract][Full Text] [Related]
10. Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets.
Murtojärvi M; Halkola AS; Airola A; Laajala TD; Mirtti T; Aittokallio T; Pahikkala T
Int J Med Inform; 2020 Jan; 133():104014. PubMed ID: 31783311
[TBL] [Abstract][Full Text] [Related]
11. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Ross-Adams H; Lamb AD; Dunning MJ; Halim S; Lindberg J; Massie CM; Egevad LA; Russell R; Ramos-Montoya A; Vowler SL; Sharma NL; Kay J; Whitaker H; Clark J; Hurst R; Gnanapragasam VJ; Shah NC; Warren AY; Cooper CS; Lynch AG; Stark R; Mills IG; Grönberg H; Neal DE;
EBioMedicine; 2015 Sep; 2(9):1133-44. PubMed ID: 26501111
[TBL] [Abstract][Full Text] [Related]
12. Re-evaluation of publicly available gene-expression databases using machine-learning yields a maximum prognostic power in breast cancer.
Tschodu D; Lippoldt J; Gottheil P; Wegscheider AS; Käs JA; Niendorf A
Sci Rep; 2023 Oct; 13(1):16402. PubMed ID: 37798300
[TBL] [Abstract][Full Text] [Related]
13. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
14. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.
You S; Knudsen BS; Erho N; Alshalalfa M; Takhar M; Al-Deen Ashab H; Davicioni E; Karnes RJ; Klein EA; Den RB; Ross AE; Schaeffer EM; Garraway IP; Kim J; Freeman MR
Cancer Res; 2016 Sep; 76(17):4948-58. PubMed ID: 27302169
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
[TBL] [Abstract][Full Text] [Related]
16. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract][Full Text] [Related]
17. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
[TBL] [Abstract][Full Text] [Related]
18. DESNT: A Poor Prognosis Category of Human Prostate Cancer.
Luca BA; Brewer DS; Edwards DR; Edwards S; Whitaker HC; Merson S; Dennis N; Cooper RA; Hazell S; Warren AY; ; Eeles R; Lynch AG; Ross-Adams H; Lamb AD; Neal DE; Sethia K; Mills RD; Ball RY; Curley H; Clark J; Moulton V; Cooper CS
Eur Urol Focus; 2018 Dec; 4(6):842-850. PubMed ID: 28753852
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Omics and Statistical Learning Integration for the Discovery and Validation of Novel Diagnostic Signatures in Colorectal Cancer.
Long NP; Park S; Anh NH; Nghi TD; Yoon SJ; Park JH; Lim J; Kwon SW
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642095
[TBL] [Abstract][Full Text] [Related]
20. A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases.
Ong CW; Maxwell P; Alvi MA; McQuaid S; Waugh D; Mills I; Salto-Tellez M
J Pathol Clin Res; 2018 Apr; 4(2):103-113. PubMed ID: 29665325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
